Lates News

After competing with Norvatis and Novartis for the acquisition of a startup company focused on weight loss medications, Pfizer has finalized the acquisition of Metsera for $10 billion. Norvatis and Novartis have stated that after careful evaluation, they have decided not to increase their acquisition offer and will continue to focus on business expansion and other acquisition opportunities. According to the agreement, Pfizer will complete the transaction at a price of up to $86.25 per share, including an initial cash payment of $65.60 per share and an additional consideration of up to $20.65 per share if certain performance targets are met.